Anavex Life Sciences received a new U.S. patent for ANAVEX®2-73, enhancing its treatment options for CNS disorders.
Quiver AI Summary
Anavex Life Sciences Corp. announced the issuance of a new U.S. Patent No. 12,180,174 for its drug candidate ANAVEX®2-73 (blarcamesine), which covers crystalline forms of the dihydrogen phosphate salt, as well as transdermal patches and enteric-coated oral dosage formulations aimed at treating neurodegenerative disorders like Alzheimer’s and Parkinson’s diseases. This patent, expected to be valid until at least July 2039, enhances Anavex's existing patent portfolio and reflects the company's commitment to developing innovative therapeutic formulations. CEO Christopher U. Missling highlighted the potential benefits of these new crystalline forms for patient compliance and ease of administration. The press release also notes the challenges and significance of crystal polymorphism in pharmaceuticals and underscores Anavex's efforts to optimize its drug formulations for improved efficacy and safety.
Potential Positives
- Anavex Life Sciences Corp. has been issued a new U.S. Patent (No. 12,180,174) for its innovative therapeutic agent, ANAVEX®2-73 (blarcamesine), which can enhance its competitive edge in the biopharmaceutical market.
- The patent covers crystalline forms and various delivery methods, including transdermal patches, which may simplify administration and improve patient compliance.
- This newly granted patent extends the company's existing intellectual property portfolio, providing further protection for its lead drug candidate, ANAVEX®2-73, until at least July 2039.
- The patent illustrates Anavex's expertise in drug formulation, potentially translating into improved efficacy and reduced side effects for patients with neurodegenerative disorders.
Potential Negatives
- The press release primarily focuses on the issuance of a new patent, which may indicate to investors that the company is relying on intellectual property protection rather than demonstrating significant progress in clinical trials or product development.
- The mention that the uniqueness of the crystalline forms and their potential benefits could imply past challenges or difficulties in achieving desired drug efficacy, which may raise concerns about the development process.
- No definitive conclusions regarding the efficacy or safety of the drug candidate ANAVEX®2-73 are provided, highlighting the ongoing uncertainty and risks associated with the product's future commercial viability.
FAQ
What is the new U.S. Patent No. 12,180,174 about?
The patent covers crystalline forms of ANAVEX®2-73 (blarcamesine) and methods for its use in treating neurodegenerative disorders.
How long will the new Anavex patent remain in force?
This patent is expected to remain in force until at least July 2039, excluding any patent term extensions.
What diseases does ANAVEX®2-73 target?
ANAVEX®2-73 aims to treat Alzheimer's, Parkinson's, Rett syndrome, schizophrenia, and other central nervous system disorders.
What are the benefits of the dihydrogen phosphate crystals?
The crystals enhance drug formulation options, allowing for effective oral dosing and convenient transdermal delivery methods.
What differentiates crystal polymorphism in pharmaceuticals?
Polymorphism allows drug substances to exist in different forms, influencing their physical properties, efficacy, and side effects in treatments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AVXL Hedge Fund Activity
We have seen 77 institutional investors add shares of $AVXL stock to their portfolio, and 49 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NWAM LLC added 910,476 shares (+inf%) to their portfolio in Q3 2024, for an estimated $5,171,503
- WEALTHGARDEN F.S. LLC added 910,476 shares (+inf%) to their portfolio in Q3 2024, for an estimated $5,171,503
- STATE STREET CORP removed 674,409 shares (-18.0%) from their portfolio in Q3 2024, for an estimated $3,830,643
- CITADEL ADVISORS LLC removed 421,313 shares (-94.3%) from their portfolio in Q3 2024, for an estimated $2,393,057
- BLACKROCK, INC. added 349,224 shares (+5.5%) to their portfolio in Q3 2024, for an estimated $1,983,592
- BANK OF AMERICA CORP /DE/ removed 325,094 shares (-54.1%) from their portfolio in Q3 2024, for an estimated $1,846,533
- MILLENNIUM MANAGEMENT LLC added 303,172 shares (+801.7%) to their portfolio in Q3 2024, for an estimated $1,722,016
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today it was issued a new U.S. Patent No. 12,180,174 entitled “A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF” from the United States Patent and Trademark Office (USPTO) for its U.S. Patent Application Serial Number USSN: 17/978,818. This new patent claims crystalline forms of the dihydrogen phosphate salt of ANAVEX®2-73 (blarcamesine), freebase, transdermal patches and enteric coated oral dosage forms including the same for neuroprotection and treatment of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and other disorders.
Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) patent portfolio, which includes several U.S. Patents, including U.S. Patent Nos. 10,413,519; 10,966,952; 11,661,405; and 11,498,908.
“The issuance of this U.S. Patent again showcases our expertise in identifying and pursuing novel therapeutic forms and formulations that are rooted in science,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. He further added: “We believe the unique properties of the dihydrogen phosphate crystals make it possible in addition to convenient once daily oral dosing to also deliver the active (ANAVEX®2-73 freebase) in transdermal patches, which could simplify further the administration and boost patients’ compliance. As such, we believe that the addition of the dihydrogen phosphate crystals to our platform could greatly benefit the patients at large.”
About Crystal Forms
Crystal polymorphism is a unique phenomenon related to chiral compounds, wherein the compounds may crystallize into different crystal structures or crystal forms under different conditions and/or processes. Specifically for pharmaceuticals, polymorphic forms of drug substances ‘exist in different crystalline forms which differ in their physical properties’. 1 These property differences may result in direct medical implications, such as ease of formulation, increased efficacy, and reduced side effects. For example, the widely used analgesic drug, acetaminophen has three polymorphic forms, I, II, and III, among which only Form I is made into commercial dosage forms as the other two forms are either meta-stable or unstable. 2 Nonetheless, uncovering an optimal crystal form is NOT an easy or straightforward task, because there are so many variables and possibilities involved, and chance of success lies heavily on the researcher’s experience and insights into the compounds in question. Both ANAVEX®2-73 (blarcamesine) and ANAVEX®19-144 have the potential to form different crystal forms. Through its deep understanding and abundance experience with these two compounds, Anavex was successful in discovering crystal forms of ANAVEX®2-73 (blarcamesine) and ANAVEX®19-144 that have advantageous physiochemical and/or pharmacological properties.
This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 ( blarcamesine ), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com . You can also connect with the Company on Twitter, Facebook , Instagram , and LinkedIn .
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email:
[email protected]
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email:
[email protected]
1 ICH HARMONISED TRIPARTITE GUIDELINE, SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS: CHEMICAL SUBSTANCES Q6A, Current Step 4 version dated 6 October 1999, page 8.
2 Lee E.H., “A practical guide to pharmaceutical polymorph screening & selection,” Asian Journal of Pharmaceutical Sciences, Vol 9, Issue 4, August 2014, Pages 163-175.